Open AccessA randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV
Author(s) -
Constance A. Benson,
Charles van der Horst,
Anthony LaMarca,
David W. Haas,
Cheryl McDonald,
Corklin R. Steinhart,
John Rublein,
Joseph B. Quinn,
Elsa Mondou,
Franck Rousseau
Publication year - 2004
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200411190-00007
Subject(s) - emtricitabine , lamivudine , regimen , zidovudine , stavudine , medicine , nucleoside reverse transcriptase inhibitor , reverse transcriptase inhibitor , virology , viral load , pharmacology , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , viral disease , hepatitis b virus
Once daily (QD) dosing facilitates regimen simplification and adherence to antiretroviral therapy. Emtricitabine (FTC) QD is a newly approved nucleoside reverse transcriptase inhibitor compared in this study to twice daily lamivudine (3TC BID).